Acerus Announces Acceptance of Two NATESTO® Clinical Studies for Presentation at the American Urological Association Annual Scientific Program

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Feb 05, 2020 08:30 am

Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:ASP, OTCQB:ASPCF) today announced the acceptance of two NATESTO® clinical studies for presentation at the American Urological Association’s AUA2020 Scientific Program. The AUA2020 meeting will be held May 15th – 18th in Washington, DC.

Results of the NATESTO® Spermatogenesis Study have been accepted as a Podium Session, by lead author Thomas Masterson, MD, Urology Fellow in the Department of Urology at the University of Miami School of Medicine. The NATESTO® Spermatogenesis Study has been conducted under the direction of principal investigator Ranjith Ramasamy, MD, Associate Professor and Director of Reproductive Urology, Department of Urology, University of Miami School of Medicine.

Presentation Details:

  • Presenting Author: Thomas Masterson, MD, Fellow, Department of Urology, University of Miami School of Medicine
  • Abstract Title: The effect of NATESTO® on spermatogenesis, reproductive hormones, and hypogonadal symptoms. A phase IV study.
  • Abstract Number: 20-78

Additionally, the results of a NATESTO® retrospective analysis being conducted under the supervision of principal investigator Parviz Kavoussi, MD, FACS have been accepted for a Moderated Poster Session. Dr. Kavoussi is a Reproductive Urologist at Austin Fertility & Reproductive Medicine/Westlake IVF. He is also Adjunct Assistant Professor, Department of Urology, at the University of Texas Health Sciences Center at San Antonio, as well as Adjunct Assistant Professor at the University of Texas at Austin.

Presentation Details:

  • Presenting Author: Parviz Kavoussi, MD, Reproductive Urologist, Austin Fertility & Reproductive Medicine/Westlake IVF
  • Abstract Title: Converting men from clomiphene citrate to NATESTO® for hypogonadism improves libido, maintains semen parameters, and reduces estradiol.
  • Abstract ID: 20-6651

Selection of the abstracts for publication in the press program does not imply endorsement of NATESTO® by AUA.

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of men’s health. The Company commercializes its products via its own salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Acerus’ shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit and follow us on Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the commercial performance of NATESTO® and the impact of the Spermatogenesis study on such performance, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 4, 2019 which is available at Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Edward Gudaitis
President and Chief Executive Officer
[email protected]
(905) 817-8194

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).